| Description | This is a recombinant human antibody that specifically targets Human TIGIT. HuTIGl-IgGl.AA effectively binds to wild type human TIGIT with an EC5o of 1.28 nM. These monoclonal antibodies possess the ability to activate T cells and natural killer cells significantly by preventing the interaction between TIGIT and CD 155. They have potential applications in cancer treatment, infectious disease treatment, and other areas. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG1, kappa |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | WB; FC; ELISA; Block |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TIGIT |
| Alternative Name | T Cell Immunoreceptor With Ig And ITIM Domains; V-Set And Immunoglobulin Domain-Containing Protein 9; V-Set And Transmembrane Domain-Containing Protein 3; T-Cell Immunoreceptor With Ig And ITIM Domains; VSIG9, VSTM3; VSIG9 |
| Gene ID | 201633 |
| UniProt | Q495A1 |
| Research Area | Immunology |
